| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
|
Purity: ≥98%
Tropisetron HCl (Navoban; ICS-205930; ICS 205-930), the hydrochloride salt of Tropisetron which is an anti-emetic drug, is a novel, potent and selective 5-HT3 receptor antagonist and α7-nicotinic receptor agonist that has been approved for the treatment of chemotherapy-induced nausea and vomiting. Tropisetron binds with great affinity to both 5HT3R and th α7 nAChR. With respect to the other nicotinic subtypes tested, tropisetron has very little affinity.
| Targets |
5-HT3 Receptor ( IC50 = 70.1 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Cell Assay |
Cell survival was increased to an average of 105% in retinal ganglion cells (RGCs) pretreated with 100 nM tropisetron before glutamate, in comparison to controls. Tropisetron is thought to be an efficient neuroprotective agent against glutamate-induced excitotoxicity, as it is mediated by α7 nAChR activation, according to inhibition studies conducted with the alpha7 nAChR antagonist MLA (10 nM2). p38 MAPK levels linked to excitotoxicity were dramatically reduced by tropisetron from an average of 15 ng/ml to 6 ng/ml, while pAkt levels were not affected in any appreciable way. Tropisetron over-expresses the CB(1) receptors at both transcriptional and protein levels, inhibits the phosphatase activity of calcineurin significantly (but not granisetron), and lowers the amount of cAMP in cerebellar granule neurons
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C17H21CLN2O2
|
|---|---|
| Molecular Weight |
320.81
|
| Exact Mass |
320.13
|
| Elemental Analysis |
C, 64.57; H, 6.92; Cl, 10.59; N, 8.37; O, 9.56
|
| CAS # |
105826-92-4
|
| Related CAS # |
Tropisetron; 89565-68-4
|
| Appearance |
Solid powder
|
| SMILES |
CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43.Cl
|
| InChi Key |
XIEGSJAEZIGKSA-KOQCZNHOSA-N
|
| InChi Code |
InChI=1S/C17H20N2O2.ClH/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16;/h2-5,10-13,18H,6-9H2,1H3;1H/t11-,12+,13?;
|
| Chemical Name |
[(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate;hydrochloride
|
| Synonyms |
ICS-205-930; Tropisetron; ICS-205930; ICS 205930; ICS205930; ICS 205-930; Tropisetron HCl; Brand name: Navoban
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1171 mL | 15.5855 mL | 31.1711 mL | |
| 5 mM | 0.6234 mL | 3.1171 mL | 6.2342 mL | |
| 10 mM | 0.3117 mL | 1.5586 mL | 3.1171 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05564286 | Recruiting | Drug: Fosaprepitant Drug: tropisetron |
Cervical Cancer Antiemetic |
Shantou University Medical College |
July 1, 2021 | Phase 3 |
| NCT05533281 | Recruiting | Drug: tropisetron Drug: metoclopramide |
Nausea and Vomiting | The Second Affiliated Hospital of Chongqing Medical University |
September 15, 2022 | Early Phase 1 |
| NCT05242874 | Active Recruiting |
Drug: Fosaprepitant , Tropisetron and Olanzapine Drug: Fosaprepitant , Tropisetron, Dexamethasone and Olanzapine |
Chemotherapy-induced Nausea and Vomiting |
Henan Cancer Hospital | January 1, 2022 | Phase 3 |
| NCT04817189 | Recruiting | Drug: NEPA (300mg netupitant /0.5mg palonosetron) Drug: Dexamethasone, 8 mg (oral) or equivalent IV dose |
Chemotherapy-induced Nausea and Vomiting |
Helsinn Healthcare SA | February 1, 2021 | Phase 4 |
| NCT00435370 | Completed | Drug: Tropisetron Drug: Placebo |
Smoking Cessation Schizophrenia |
Baylor College of Medicine | November 2006 | Phase 3 |
 |
|---|
 |
 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA